Cover Image
市場調查報告書

人類乳突病毒(HPV)相關的癌症:開發中產品分析

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 255958
出版日期 內容資訊 英文 229 Pages
訂單完成後即時交付
價格
Back to Top
人類乳突病毒(HPV)相關的癌症:開發中產品分析 Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 229 Pages
簡介

人類乳突病毒(HPV)是生殖器官最常見的病毒感染。已知人類乳突病毒(HPV)與數種類型的癌症相關。危險因素包括吸煙,免疫系統衰弱,長期口服避孕藥和慢性炎症等。人類乳突病毒(HPV)相關癌症由於症狀出現得極晚,一般症狀出現時已是末期,治療非常困難。

本報告提供全球人類乳突病毒(HPV)相關的癌症治療藥之開發趨勢調查,提供開發中產品的各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,該部門的最新趨勢,主要企業的檢討等資訊。

簡介

  • 調查範圍

HPV相關的癌症概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的治療藥
  • 各大學/機關的治療藥
  • 企業開發中的產品
  • 大學/機關研究中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Abion Inc
  • Admedus Ltd
  • Advaxis Inc
  • Antigen Express Inc
  • Atara Biotherapeutics Inc
  • BioNTech AG
  • Cancer Research Technology Ltd
  • Cell Medica Ltd
  • Etubics Corp
  • EyeGene Inc
  • Formune SL
  • Genexine Inc
  • Hookipa Biotech AG
  • iBio Inc
  • Immunovaccine Inc
  • Inovio Pharmaceuticals Inc
  • ISA Pharmaceuticals BV
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Kite Pharma Inc
  • Lion Biotechnologies Inc
  • MedImmune LLC
  • Millennium Pharmaceuticals Inc
  • NeoImmuneTech Inc
  • Onconova Therapeutics Inc
  • Oryx GmbH & Co KG
  • PDS Biotechnology Corp
  • Peregrine Pharmaceuticals Inc
  • Profectus BioSciences Inc
  • Rottapharm Biotech Srl
  • Selecta Biosciences Inc
  • Shantha Biotechnics Ltd
  • Shuttle Pharmaceuticals LLC
  • Sirnaomics Inc
  • Solon Eiendom ASA
  • Theravectys SA
  • THEVAX Genetics Vaccine USA Inc
  • Tomegavax Inc
  • Transgene SA
  • UbiVac LLC
  • Vaccibody AS
  • Vault Pharma Inc
  • Virometix AG
  • VLPbio

藥物簡介

暫停中的計劃

開發中止的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9206IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2017, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 14, 5, 41 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 11 and 3 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Human Papillomavirus (HPV) Associated Cancer - Overview
    • Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development
    • Abion Inc
    • Admedus Ltd
    • Advaxis Inc
    • Antigen Express Inc
    • Atara Biotherapeutics Inc
    • BioNTech AG
    • Cancer Research Technology Ltd
    • Cell Medica Ltd
    • Etubics Corp
    • EyeGene Inc
    • Formune SL
    • Genexine Inc
    • Hookipa Biotech AG
    • iBio Inc
    • Immunovaccine Inc
    • Inovio Pharmaceuticals Inc
    • ISA Pharmaceuticals BV
    • Johnson & Johnson
    • Juno Therapeutics Inc
    • Karyopharm Therapeutics Inc
    • Kite Pharma Inc
    • Lion Biotechnologies Inc
    • MedImmune LLC
    • Millennium Pharmaceuticals Inc
    • NeoImmuneTech Inc
    • Onconova Therapeutics Inc
    • Oryx GmbH & Co KG
    • PDS Biotechnology Corp
    • Peregrine Pharmaceuticals Inc
    • Profectus BioSciences Inc
    • Rottapharm Biotech Srl
    • Selecta Biosciences Inc
    • Shantha Biotechnics Ltd
    • Shuttle Pharmaceuticals LLC
    • Sirnaomics Inc
    • Solon Eiendom ASA
    • Theravectys SA
    • THEVAX Genetics Vaccine USA Inc
    • Tomegavax Inc
    • Transgene SA
    • UbiVac LLC
    • Vaccibody AS
    • Vault Pharma Inc
    • Virometix AG
    • VLPbio
  • Human Papillomavirus (HPV) Associated Cancer - Drug Profiles
    • ABI-1968 - Drug Profile
    • ABN-301 - Drug Profile
    • AEH-10p - Drug Profile
    • alisertib - Drug Profile
    • Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile
    • Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile
    • ATA-368 - Drug Profile
    • AVA-1001 - Drug Profile
    • axalimogene filolisbac - Drug Profile
    • bavituximab - Drug Profile
    • BVAC-C - Drug Profile
    • Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
    • Cellular Immunotherapy for HPV Associated Cervical Cancer - Drug Profile
    • Cellular Immunotherapy to Target HPV E6 and E7 Protein for Oncology - Drug Profile
    • Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile
    • Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile
    • CerviVax - Drug Profile
    • CMD-004 - Drug Profile
    • CUE-101 - Drug Profile
    • CUE-201 - Drug Profile
    • DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile
    • DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
    • DPV-001 - Drug Profile
    • DPV-003 - Drug Profile
    • DPXE-7 - Drug Profile
    • EDA-HPVE7 - Drug Profile
    • EG-HPV - Drug Profile
    • Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile
    • ETBX-041 - Drug Profile
    • Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
    • Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile
    • GX-188E - Drug Profile
    • HB-201 - Drug Profile
    • HPViNT - Drug Profile
    • human papillomavirus (7-valent) vaccine - Drug Profile
    • human papillomavirus [Serotype 16] vaccine - Drug Profile
    • human papillomavirus [serotypes 16] vaccine - Drug Profile
    • human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine biosimilar - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • INO-3106 - Drug Profile
    • INO-3112 - Drug Profile
    • ISA-101 - Drug Profile
    • ISA-201 - Drug Profile
    • KITE-439 - Drug Profile
    • LN-145 - Drug Profile
    • Monoclonal Antibody Conjugate to Target CD40 for HPV Associated Cervical, Head And Neck Cancer - Drug Profile
    • Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
    • Monoclonal Antibody to Target E6 and E7 Proteins for Oncology - Drug Profile
    • NIT-02 - Drug Profile
    • NP-001 - Drug Profile
    • NSC-721689 - Drug Profile
    • Oncolytic Virus to Target E6/E7 for HPV Associated Head and Neck Cancer - Drug Profile
    • PDS-0101 - Drug Profile
    • PVX-01 - Drug Profile
    • Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV Associated Cervical Cancer - Drug Profile
    • rigosertib sodium - Drug Profile
    • sdCMV-002 - Drug Profile
    • SEL-701 - Drug Profile
    • Small Molecules for Solid Tumors and HPV Associated Cancer - Drug Profile
    • Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer - Drug Profile
    • SP-259 - Drug Profile
    • STP-900 - Drug Profile
    • Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
    • TA-CIN - Drug Profile
    • TG-4001 - Drug Profile
    • Tricurin - Drug Profile
    • TVGV-1 - Drug Profile
    • TVGV-2 - Drug Profile
    • Vacc-HPV - Drug Profile
    • Vaccine for HIV and HPV Associated Cancer - Drug Profile
    • Vaccine for HPV Associated Cancer - Drug Profile
    • Vaccine for HPV Associated Cancers - Drug Profile
    • Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Vaccine for HPV Associated Cervical Cancer - Drug Profile
    • Vaccine for HPV Associated Non-Melanoma Skin Cancer - Drug Profile
    • Vaccine for Human Papillomavirus Associated Cervical Cancer - Drug Profile
    • VB-1016 - Drug Profile
    • verdinexor - Drug Profile
    • VGX-3100 - Drug Profile
    • Vicoryx - Drug Profile
    • VMT-2 - Drug Profile
    • VPI-241 - Drug Profile
    • Vvax-001 - Drug Profile
  • Human Papillomavirus (HPV) Associated Cancer - Dormant Projects
  • Human Papillomavirus (HPV) Associated Cancer - Discontinued Products
  • Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abion Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Ltd, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cell Medica Ltd, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corp, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Formune SL, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Hookipa Biotech AG, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Juno Therapeutics Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune LLC, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by NeoImmuneTech Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co KG, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by PDS Biotechnology Corp, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Rottapharm Biotech Srl, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Ltd, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shuttle Pharmaceuticals LLC, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Solon Eiendom ASA, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Tomegavax Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac LLC, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vault Pharma Inc, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Human Papillomavirus (HPV) Associated Cancer - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top